Studies of Daiichi Sankyo’s Olmesartan Show “No Clear Evidence” Of CV Risk In Diabetes Patients, FDA Finds
This article was originally published in PharmAsia News
Executive Summary
Although data raise “concern of possible increased CV risk” with use of high-dose olmesartan in diabetic patients, FDA concludes that use of the drug in this group can continue.